Ethinylestradiol/Chlormadinone Acetate for Use in Dermatological Disorders

The document from 2011 reported on the effectiveness of ethinylestradiol/chlormadinone acetate (EE/CMA) in treating dermatological disorders related to androgen excess, including androgenetic alopecia, acne, and hirsutism, through four case reports. The patients, ranging from 19 to 32 years old, showed improvements in their conditions after 6 months of EE/CMA treatment. The treatment was well-tolerated, and while the document highlighted the need for larger studies to confirm these findings, it suggested that EE/CMA could be a valuable treatment option for these disorders. The document also reviewed other treatments for these conditions, noting the importance of targeting androgen excess or sensitivity, but pointed out that ongoing treatment is necessary as none result in full hair recovery.